|
|
|
|
| LEADER |
03380nma a2200889 u 4500 |
| 001 |
EB002173079 |
| 003 |
EBX01000000000000001310856 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230811 ||| eng |
| 020 |
|
|
|a books978-3-0365-7433-2
|
| 020 |
|
|
|a 9783036574325
|
| 020 |
|
|
|a 9783036574332
|
| 100 |
1 |
|
|a Serena, Mazzucchelli
|
| 245 |
0 |
0 |
|a Natural Nanoparticle for Cancer Diagnosis and Treatment
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
| 300 |
|
|
|a 1 electronic resource (208 p.)
|
| 653 |
|
|
|a antitumor effect
|
| 653 |
|
|
|a tumor-targeting probes
|
| 653 |
|
|
|a microparticulate system
|
| 653 |
|
|
|a luteolin
|
| 653 |
|
|
|a toxicity assessment
|
| 653 |
|
|
|a natural nanocarriers
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a fucoidan nanoparticle
|
| 653 |
|
|
|a gemcitabine
|
| 653 |
|
|
|a pancreatic cancer
|
| 653 |
|
|
|a safety
|
| 653 |
|
|
|a exosomes
|
| 653 |
|
|
|a chemoresistance
|
| 653 |
|
|
|a biomimetics
|
| 653 |
|
|
|a imaging
|
| 653 |
|
|
|a Garcinia mangostana L.
|
| 653 |
|
|
|a marine polysaccharide
|
| 653 |
|
|
|a Technology: general issues / bicssc
|
| 653 |
|
|
|a siRNA
|
| 653 |
|
|
|a RNA interference
|
| 653 |
|
|
|a novel cancer treatment alternatives
|
| 653 |
|
|
|a nanocarrier
|
| 653 |
|
|
|a vesicles
|
| 653 |
|
|
|a RRM2
|
| 653 |
|
|
|a nanotechnology
|
| 653 |
|
|
|a natural cancer therapies
|
| 653 |
|
|
|a parenteral administration
|
| 653 |
|
|
|a cancer theranostic
|
| 653 |
|
|
|a in vivo study
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a cancer therapy
|
| 653 |
|
|
|a natural anticancer compounds
|
| 653 |
|
|
|a nanoparticles
|
| 653 |
|
|
|a anti-metastasis
|
| 653 |
|
|
|a topical gel
|
| 653 |
|
|
|a tumor targeting
|
| 653 |
|
|
|a miRNA
|
| 653 |
|
|
|a irritation study
|
| 653 |
|
|
|a biosensing
|
| 653 |
|
|
|a H. pylori
|
| 653 |
|
|
|a natural nanoparticles
|
| 653 |
|
|
|a ferritin
|
| 653 |
|
|
|a drug delivery
|
| 653 |
|
|
|a antibiotic therapy
|
| 653 |
|
|
|a optimization
|
| 653 |
|
|
|a deferasirox
|
| 653 |
|
|
|a buoyancy
|
| 653 |
|
|
|a bacterial membrane vesicles
|
| 653 |
|
|
|a natural carbon nanodots
|
| 653 |
|
|
|a chemotherapeutic agents targeted delivery
|
| 700 |
1 |
|
|a Serena, Mazzucchelli
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-0365-7433-2
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/7232
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/100770
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 600
|
| 520 |
|
|
|a This reprint is focused on the exploitation of natural nanoparticles for cancer diagnosis and treatment. It compiles articles related to exosomes and protein nanocages, but also presents the use of some organic natural compounds in cancer treatment, which have been extensively studied as agents for cancer treatment since their biological nature guarantees a better safety, biocompatibility, and biodegradability profile in comparison to synthetic nanoparticles and drugs. These features are strongly appealing in order to face cancer, where the development of tumor-targeted specific devices and the use of natural compounds could be useful in improving patient compliance.
|